Literature DB >> 6107936

LDS-25 as a discriminative stimulus for response selection by pigeons.

T U Järbe.   

Abstract

Pigeons (N=4) were trained to discriminate between the effects induced by intramuscular (IM) injections of d-LSD and saline using a discrete-trial discrimination paradigm (choice between left and right hand key) in a conventional operant box. The solutions were administered IM 15 min prior to the sessions. A FR 15 schedule was in operation to produce food. Which of the two keys was correct on a given training session depended upon whether LSD or saline had been given. Three of the birds were trained and maintained with a dose of 40 microgram/kg of LSD and the fourth pigeon finally was maintained on 50 microgram/kg of LSD. The dose resulting in 50% LSD appropriate responding (ED50) was 18 microgram/kg and the median time-interval for the decay of the LSD stimulus (40 microgram/kg) was 84 min. Tests with psilocybin (ED50=0.55 mg/kg) and N,N-dimethyltryptamine (ED50=5.7 mg/kg) resulted in responding appropriate for the LSD training condition. Mescaline injections above 10 mg/kg severely suppressed responding. The few responses emitted after tests with 15 and 20 mg/kg of mescaline were directed to the LSD associated key. Tests with BOL (0.1 to 3 mg/kg) as well as three other psychotropic drugs (delta 9-tetrahydrocannabinol, morphine and, pentobarbital) did not result in responding above 50%) LSD appropriate responses. As a possible antidote, methergoline, a pubetative antagonist of post-synaptic serotonin receptor sites, was administered 75 min prior to testing the cueing properties of LSD. No definitive role for a blocking effect of the LSD-cue is provided by the present data.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107936     DOI: 10.1016/0091-3057(80)90279-8

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.

Authors:  Danuta Marona-Lewicka; Ronald A Thisted; David E Nichols
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

Review 2.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

3.  Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.

Authors:  Michael B Gatch; Sean B Dolan; Michael J Forster
Journal:  Behav Pharmacol       Date:  2017-08       Impact factor: 2.293

Review 4.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Neuropharmacology       Date:  2011-01-20       Impact factor: 5.250

5.  Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.

Authors:  Michael B Gatch; Margaret A Rutledge; Theresa Carbonaro; Michael J Forster
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

6.  Discriminative stimulus effects of N,N-diisopropyltryptamine.

Authors:  Theresa M Carbonaro; Michael J Forster; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2012-10-16       Impact factor: 4.530

Review 7.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

8.  Psilocybin-induced stimulus control in the rat.

Authors:  J C Winter; K C Rice; D J Amorosi; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2007-06-22       Impact factor: 3.533

9.  How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Authors:  Manon van den Berg; Igor Magaraggia; Rudy Schreiber; Todd M Hillhouse; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2022-03-29       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.